JP2023550462A5 - - Google Patents
Info
- Publication number
- JP2023550462A5 JP2023550462A5 JP2023530591A JP2023530591A JP2023550462A5 JP 2023550462 A5 JP2023550462 A5 JP 2023550462A5 JP 2023530591 A JP2023530591 A JP 2023530591A JP 2023530591 A JP2023530591 A JP 2023530591A JP 2023550462 A5 JP2023550462 A5 JP 2023550462A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- radiopharmaceutical composition
- cancer
- her3
- radionuclide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063116225P | 2020-11-20 | 2020-11-20 | |
| US63/116,225 | 2020-11-20 | ||
| US202063118181P | 2020-11-25 | 2020-11-25 | |
| US63/118,181 | 2020-11-25 | ||
| US202163226699P | 2021-07-28 | 2021-07-28 | |
| US63/226,699 | 2021-07-28 | ||
| US202163250725P | 2021-09-30 | 2021-09-30 | |
| US63/250,725 | 2021-09-30 | ||
| PCT/US2021/056259 WO2022087416A1 (en) | 2020-10-22 | 2021-10-22 | Combination radioimmunotherapy and cd47 blockade in the treatment of cancer |
| USPCT/US2021/056259 | 2021-10-22 | ||
| PCT/US2021/060370 WO2022109404A1 (en) | 2020-11-20 | 2021-11-22 | Her3 radioimmunotherapy for the treatment of solid cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550462A JP2023550462A (ja) | 2023-12-01 |
| JP2023550462A5 true JP2023550462A5 (enExample) | 2024-11-29 |
Family
ID=81709768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023530591A Pending JP2023550462A (ja) | 2020-11-20 | 2021-11-22 | 固形がんの治療のためのｈｅｒ３放射免疫治療薬 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4247430A4 (enExample) |
| JP (1) | JP2023550462A (enExample) |
| KR (1) | KR20230128271A (enExample) |
| AU (1) | AU2021382717A1 (enExample) |
| CA (1) | CA3199259A1 (enExample) |
| IL (1) | IL303030A (enExample) |
| MX (1) | MX2023005940A (enExample) |
| WO (1) | WO2022109404A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023546679A (ja) * | 2020-10-22 | 2023-11-07 | アクティニウム ファーマシューティカルズ インコーポレイテッド | がん治療における放射免疫療法とｃｄ４７遮断の併用 |
| JP2024528081A (ja) * | 2021-07-28 | 2024-07-26 | アクティニウム ファーマシューティカルズ インコーポレイテッド | 癌の治療における放射免疫療法及びｃｄ４７遮断薬の組み合わせ |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2422291C (en) * | 2000-09-15 | 2011-03-08 | Sloan-Kettering Institute For Cancer Research | Targeted alpha particle therapy using actinium-225 conjugates |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| AU2010284018C1 (en) * | 2009-08-21 | 2015-10-15 | Merrimack Pharmaceuticals, Inc. | Antibodies against the ectodomain of ErbB3 and uses thereof |
| AU2011286407A1 (en) * | 2010-08-06 | 2013-02-21 | Amgen | Use of HER3 binding agents in prostate treatment |
| JP2018524373A (ja) * | 2015-07-15 | 2018-08-30 | ザイムワークス，インコーポレイテッド | 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト |
| US20220008570A1 (en) * | 2018-12-21 | 2022-01-13 | Actinium Pharmaceuticals, Inc. | Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer |
-
2021
- 2021-11-22 EP EP21895766.0A patent/EP4247430A4/en active Pending
- 2021-11-22 JP JP2023530591A patent/JP2023550462A/ja active Pending
- 2021-11-22 MX MX2023005940A patent/MX2023005940A/es unknown
- 2021-11-22 AU AU2021382717A patent/AU2021382717A1/en active Pending
- 2021-11-22 IL IL303030A patent/IL303030A/en unknown
- 2021-11-22 CA CA3199259A patent/CA3199259A1/en active Pending
- 2021-11-22 WO PCT/US2021/060370 patent/WO2022109404A1/en not_active Ceased
- 2021-11-22 KR KR1020237020749A patent/KR20230128271A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU709694B2 (en) | Methods of treating colon cancer utilizing tumor-specific antibodies | |
| US9849176B2 (en) | RS7 antibodies | |
| CN101972478B (zh) | 抗体治疗 | |
| JP7475283B2 (ja) | キレート化された放射性核種に対する抗体 | |
| AU2019234468B2 (en) | Bispecific binding agents and uses thereof | |
| CN100548374C (zh) | 用ⅲ类抗cea单克隆抗体和治疗剂进行联合治疗 | |
| JP2006521286A5 (enExample) | ||
| CN106573983B (zh) | 用于在癌症的预防和/或治疗中使用的放射性标记的抗体片段 | |
| DeNardo | Radioimmunodetection and therapy of breast cancer | |
| JP2021521245A (ja) | キレート化された放射性核種に対する抗体および除去剤 | |
| JP2025518493A5 (enExample) | ||
| US20250281654A1 (en) | Methods for treating cancer using combinations of epigenetic therapies and radioconjugate targeting agents | |
| JP2023550462A (ja) | 固形がんの治療のためのｈｅｒ３放射免疫治療薬 | |
| JP2022521773A5 (enExample) | ||
| JP2023518818A5 (enExample) | ||
| JP2024523438A5 (enExample) | ||
| WO2017061602A1 (ja) | Ｃｄ１４７分子に特異的に結合する抗体およびその利用 | |
| JP2023546277A5 (enExample) | ||
| JP2001505203A (ja) | 抗原ａ３３に結合するヒト化抗体を用いた新形成の治療方法 | |
| WO2025089383A1 (ja) | ２２５Ａｃ標識抗ＣＤＨ３抗体 | |
| HK1139316B (en) | Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents | |
| Koppe | Surgery and radioimmunotherapy in peritoneal carcinomatosis of colorectal origin. | |
| HK1139316A (en) | Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents | |
| BR112017001782B1 (pt) | Domínio variável de cadeia pesada radiomarcado derivado de anticorpo de cadeia pesada (vhh), ou um fragmento funcional do mesmo, seu uso, e composição farmacêutica | |
| HK1125030B (en) | Rs7 antibodies |